This report was generated in response to material institutional position changes in Pfizer Inc. (PFE) as reflected in the most recent 13F filings. No discrete corporate news events were identified in the 30 days preceding this report's generation date of 2026-06-01. The prior cycle's summary noted Pfizer's trailing twelve-month performance as the primary fundamental backdrop for current institutional activity [Brief - 2026-05-24].
Pfizer's trailing twelve-month revenue stood at $63.32 billion as of the quarter ending 2026-03-29, representing year-over-year growth of 5.37%. Net income for the same period was $7.49 billion, producing a net margin of 11.83% and an operating margin of 35.40%. Earnings per share declined 9.62% year-over-year. The company carried $1.70 billion in cash against total debt of $64.46 billion. The price-to-earnings ratio was recorded at 19.98 [SEC 10-Q - PFE - 2026-03-29].
Institutional ownership data from the most recent 13F filings reflected divergent positioning. Citadel reduced its PFE position by 17% [SEC 13F - Citadel - Q1 2026]. AQR Capital added 21% to its existing position [SEC 13F - AQR Capital - Q1 2026], while Millennium Management increased its holding by 9.9% [SEC 13F - Millennium - Q1 2026]. No insider transaction data from SEC Form 4 filings was provided for this reporting cycle.
The prevailing macroeconomic rate environment shows the 10-year US Treasury yield at 4.45% and the 2-year yield at 3.99%, producing a normal yield curve spread of approximately 46 basis points [FRED DGS10] [FRED DGS2]. This rate configuration represents the broader fixed-income context within which large-cap pharmaceutical equities such as PFE are currently priced.